A US-based global R&D team was developing a long-term product roadmap for China but lacked evidence-based insight into the country’s evolving disease burden, testing patterns, and provincial readiness. They needed reliable data to determine which assays should be prioritized for China-specific innovation.
We combined macroeconomic indicators, provincial data, disease trends, and IVD testing volumes to identify priority demand areas for the near and long term.
By layering macroeconomic data with province-level disease patterns, we enhanced the analysis to provide actionable insights at both national and provincial levels across China.
This provided a clear understanding of long-term demand patterns and areas where testing needs were expected to grow.
Our data, enriched with detailed disease trend analysis, enabled the client to identify high-potential assay candidates for development in China.
By further incorporating macroeconomic data, the client could assess the affordability and readiness of each province to adopt the new assays, allowing them to strategically plan a phased, China-specific product rollout.
Clearstate’s inputs are now part of the client’s ongoing R&D planning cycle.